David Gilman Partner
David has spent the past 25 years working to assist clients’ life science innovation strategies. This work has included a range of portfolio, drug development, investment, transactional and partnering strategies. While the therapeutic span of David’s work has crossed a broad swath of medicine, particular areas of focus have included: oncology, immunology, infectious disease as well as rare and orphan segments.
Prior to joining ClearView, David spent the majority of his career as a Managing Director of The Frankel Group in NYC and Israel ultimately serving as Managing Director and lead of Huron’s Life Science Strategy team. Most recently David served as Global Head-Portfolio Management, Business Development & Licensing, Novartis Oncology In addition to client work, David has spent time teaching life sciences to business students and business to medical students and has published across drug pricing and reimbursement as well as innovation ecosystem economics.
David holds a A.B., with honors, in East Asian History from the University of Chicago and an MBA from the University of Texas at Austin.